AQR Capital Management LLC Has $115.87 Million Holdings in IQVIA Holdings Inc. $IQV

Key Points

• AQR Capital Management LLC increased its stake in IQVIA Holdings Inc. by 58.1%, owning 675,597 shares valued at approximately $115.9 million as of the latest SEC filing.
• IQVIA reported $2.81 earnings per share for the last quarter, surpassing analysts' expectations, with a revenue of $4.02 billion, a year-over-year increase of 5.3%.
• The current trading price of IQVIA shares is approximately $184.24, with a market capitalization of $31.32 billion and analysts maintaining a consensus rating of "Moderate Buy."

AQR Capital Management LLC grew its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 58.1% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 675,597 shares of the medical research company's stock after acquiring an additional 248,353 shares during the quarter. AQR Capital Management LLC owned 0.39% of IQVIA worth $115,865,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. American National Bank & Trust acquired a new position in IQVIA during the 1st quarter worth approximately $26,000. Clal Insurance Enterprises Holdings Ltd boosted its holdings in shares of IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock valued at $28,000 after buying an additional 131 shares during the last quarter. Golden State Wealth Management LLC boosted its holdings in shares of IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after buying an additional 130 shares during the last quarter. AllSquare Wealth Management LLC acquired a new stake in shares of IQVIA in the 1st quarter valued at approximately $33,000. Finally, ST Germain D J Co. Inc. boosted its holdings in shares of IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after buying an additional 76 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. UBS Group increased their price objective on IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. William Blair reissued an "outperform" rating on shares of IQVIA in a report on Wednesday, July 23rd. Evercore ISI lifted their price objective on shares of IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 9th. Redburn Partners set a $214.00 price objective on shares of IQVIA in a report on Wednesday, September 3rd. Finally, JPMorgan Chase & Co. decreased their price objective on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a report on Monday, May 19th. Eighteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, IQVIA currently has an average rating of "Moderate Buy" and an average price target of $229.64.

IQVIA Stock Performance

IQV stock traded up $2.21 during trading hours on Tuesday, hitting $189.89. 1,196,499 shares of the stock were exchanged, compared to its average volume of 1,916,591. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. The firm has a market capitalization of $32.28 billion, a P/E ratio of 27.48, a P/E/G ratio of 2.06 and a beta of 1.32. The company has a 50-day simple moving average of $180.48 and a two-hundred day simple moving average of $167.20. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $248.03.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The firm had revenue of $4.02 billion for the quarter, compared to analysts' expectations of $3.96 billion. During the same quarter last year, the business earned $2.64 EPS. The company's quarterly revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares in the company, valued at $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.